구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Stelara (ustekinumab) | Skyrizi (risankizumab-rzaa) | Tremfya (guselkumab) | Remicade® |
Overview Company | AbbVie | Johnson & Johnson | AbbVie | Johnson & Johnson | Janssen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | IL-12 / IL-23 (p40) | IL-23 p19 | IL-23 p19 | Ankylosing Spondylitis |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Crohn's Disease |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | novel object recognition test | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | novel alternative targets with improved efficacy and safety profiles to treat RA |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | IL-17 independent disease and immunogenicity. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | — |
Positioning Development positioning | — | — | — | IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | targeted metabolomics, to delineate microbial and metabolic signatures predictive of IFX induction efficacy and to explore mechanistic pathway |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | biomarkers but require external validation in independent cohorts | PASI, sPGA, IBD endoscopic scores. | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | biomarkers and safety profile were noted before and after switch |
PK/PD Half-life | ~14–19 days (SC) | 19 h | 28 h | ~15–18 days | — |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Mouse, Skin clearance (PASI75/90), endoscopic response in IBD | Mouse | Cynomolgus monkey, PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22 | Mouse, Human |
PK/PD Animal (cat.) | Rat | Mouse | Mouse | Human, NHP | Human, Mouse |
PK/PD Experiment | pd | Pharmacokinetic | Pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse | Mouse, Pig | Mouse, Human |
Toxicology Animal (cat.) | NHP | — | — | — | Human, Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Toxicology CRS | N/A | N/A | N/A | N/A | — |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Selected reported efficacy | — | PASI75 67% | — | — | — |
Clinical PASI75 | — | 67% | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02405780 | PHOENIX | — | — | ClinicalTrials.gov NCT02990806 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | PHOENIX | — | — | NCT02990806 |
Preclinical Animal (cat.) | — | — | Mouse | Mouse | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Humira (adalimumab) | Stelara (ustekinumab) | Skyrizi (risankizumab-rzaa) | Tremfya (guselkumab) | Remicade® |
Overview Company | AbbVie | Johnson & Johnson | AbbVie | Johnson & Johnson | Janssen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | IL-12 / IL-23 (p40) | IL-23 p19 | IL-23 p19 | Ankylosing Spondylitis |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Crohn's Disease |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | novel object recognition test | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | novel alternative targets with improved efficacy and safety profiles to treat RA |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. | IL-17 independent disease and immunogenicity. | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | — |
Positioning Development positioning | — | — | — | IL-23 class benchmark alongside Skyrizi, now with the broadest IBD label progression. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | targeted metabolomics, to delineate microbial and metabolic signatures predictive of IFX induction efficacy and to explore mechanistic pathway |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | biomarkers but require external validation in independent cohorts | PASI, sPGA, IBD endoscopic scores. | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | biomarkers and safety profile were noted before and after switch |
PK/PD Half-life | ~14–19 days (SC) | 19 h | 28 h | ~15–18 days | — |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Mouse, Skin clearance (PASI75/90), endoscopic response in IBD | Mouse | Cynomolgus monkey, PASI 90/100, ACR20/50, endoscopic remission, serum IL-17A/IL-22 | Mouse, Human |
PK/PD Animal (cat.) | Rat | Mouse | Mouse | Human, NHP | Human, Mouse |
PK/PD Experiment | pd | Pharmacokinetic | Pharmacokinetic | Pharmacokinetic | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse | Mouse, Pig | Mouse, Human |
Toxicology Animal (cat.) | NHP | — | — | — | Human, Mouse |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Toxicology CRS | N/A | N/A | N/A | N/A | — |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.. Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX… |
Clinical Selected reported efficacy | — | PASI75 67% | — | — | — |
Clinical PASI75 | — | 67% | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02405780 | PHOENIX | — | — | ClinicalTrials.gov NCT02990806 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | PHOENIX | — | — | NCT02990806 |
Preclinical Animal (cat.) | — | — | Mouse | Mouse | — |
추천 비교
추천 비교